Yvonne Greenstreet Sells 8,924 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet sold 8,924 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the sale, the chief executive officer directly owned 65,409 shares of the company’s stock, valued at $29,568,138.45. This represents a 12.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Yvonne Greenstreet also recently made the following trade(s):

• On Monday, August 18th, Yvonne Greenstreet sold 6,979 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $453.27, for a total transaction of $3,163,371.33.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $456.35 on Friday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $484.21. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The company has a market capitalization of $59.82 billion, a P/E ratio of -184.76 and a beta of 0.36. The company has a fifty day moving average of $441.57 and a 200-day moving average of $339.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. During the same period in the previous year, the firm posted ($0.13) EPS. The firm’s revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ALNY. Jefferies Financial Group boosted their price target on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a “buy” rating in a research note on Monday, July 7th. HC Wainwright reissued a “buy” rating and issued a $570.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, September 2nd. Piper Sandler boosted their price target on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. UBS Group boosted their price target on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Finally, Royal Bank Of Canada boosted their price target on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a research note on Friday, September 19th. Twenty-four equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $439.58.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Atlantic Union Bankshares Corp bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth approximately $30,000. SVB Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals in the first quarter worth approximately $27,000. Whipplewood Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 71 shares in the last quarter. Bessemer Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 69 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth approximately $37,000. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.